Autonomix Medical Files S-1/A, Updates Warrants & Executive Pacts

TL;DR

**AMIX is cleaning up its S-1 for IPO, but watch those new warrants and sales agreements – dilution risk is real.**

AI Summary

Autonomix Medical, Inc. filed Amendment No. 1 to its S-1 Registration Statement on September 3, 2025, primarily as an exhibits-only filing, indicating no changes to the core financial or business sections previously submitted. The filing includes new exhibits such as the Form of Placement Agent Warrant issued in a July 2025 warrant inducement transaction and an updated opinion from ArentFox Schiff LLP. Key corporate governance documents like the Amended and Restated Certificate of Incorporation and Bylaws, originally filed January 19, 2024, remain unchanged. The company also updated employment agreements for key executives, including Brad Hauser and Lori Bisson, both dated June 17, 2024. Financial agreements include an Underwriting Agreement from November 22, 2024, with Ladenburg Thalmann & Co. Inc. and an At Market Issuance Sales Agreement from February 28, 2025, with the same firm, suggesting ongoing capital-raising activities. The filing also references a July 22, 2025, warrant inducement transaction, indicating recent efforts to manage its capital structure. The company continues to operate as an emerging growth company, as indicated by its checkmark election.

Why It Matters

This exhibits-only S-1/A filing signals Autonomix Medical's continued progression towards a public offering, with updated legal and financial agreements crucial for investors to assess the company's capital structure and governance. The inclusion of new warrant forms from July 2025 and an At Market Issuance Sales Agreement from February 2025 highlights ongoing financing efforts, which could impact share dilution and valuation. For employees, updated employment agreements for executives like Brad Hauser and Lori Bisson provide clarity on leadership stability. Competitively, these financing activities suggest the company is securing capital to advance its medical device development, potentially intensifying competition in its niche market.

Risk Assessment

Risk Level: medium — The filing is an exhibits-only amendment, meaning core financial and business risks are unchanged from the original S-1. However, the inclusion of new warrant forms from a July 2025 inducement transaction and an At Market Issuance Sales Agreement from February 2025 suggests ongoing capital raising activities that could lead to significant shareholder dilution. The company's status as an 'emerging growth company' also implies a higher risk profile due to less stringent reporting requirements.

Analyst Insight

Investors should scrutinize the full S-1 filing, particularly the financial statements and risk factors, to understand the implications of the new warrant agreements and sales agreements on potential dilution and future profitability. Pay close attention to the terms of the July 2025 warrant inducement transaction and the February 2025 At Market Issuance Sales Agreement to gauge the company's capital needs and potential impact on share price.

Financial Highlights

debt To Equity

X.X

revenue

$X

operating Margin

X%

total Assets

$X

total Debt

$X

net Income

$X

eps

$X

gross Margin

X%

cash Position

$X

revenue Growth

+X%

Executive Compensation

Key Numbers

• September 3, 2025 — Filing Date (Date of S-1/A Amendment No. 1 filing)
• 333-289741 — Registration No. (SEC Registration Statement number)
• January 19, 2024 — Original Filing Date (Date of original Form 1-A POS for certain incorporated exhibits)
• November 22, 2024 — Underwriting Agreement Date (Date of agreement with Ladenburg Thalmann & Co. Inc.)
• February 28, 2025 — Sales Agreement Date (Date of At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc.)
• July 22, 2025 — Warrant Inducement Transaction Date (Date of Series B Warrant and Placement Agent Warrant issuance)
• June 17, 2024 — Executive Employment Agreement Date (Date of employment agreements for Brad Hauser and Lori Bisson)
• December 21, 2021 — Exclusive License Agreement Date (Initial agreement with Impulse Medical, Inc.)
• July 7, 2023 — License Termination Date (Termination of exclusive license with Impulse Medical, Inc.)
• July 15, 2024 — New License Agreement Date (Date of License Agreement with RF Innovations, Inc.)

Key Players & Entities

• Autonomix Medical, Inc. (company) — Registrant
• Brad Hauser (person) — Chief Executive Officer and President
• Trent Smith (person) — Chief Financial Officer and Attorney-in-fact
• Lori Bisson (person) — Vice Chair of the Board of Directors
• ArentFox Schiff LLP (company) — Legal Counsel
• Ladenburg Thalmann & Co. Inc. (company) — Underwriter and Placement Agent
• Equity Stock Transfer, LLC (company) — Warrant Agent
• Forvis Mazars, LLP (company) — Auditor
• Impulse Medical, Inc. (company) — Former License Partner
• RF Innovations, Inc. (company) — License Partner

FAQ

Industry Context

Autonomix Medical operates in the medical technology sector, likely focusing on devices or solutions for medical procedures. The sector is characterized by significant R&D investment, long product development cycles, and stringent regulatory approval processes. Companies often rely on strategic partnerships and capital raises to fund innovation and market entry.

Regulatory Implications

As a medical technology company, Autonomix Medical is subject to rigorous oversight by regulatory bodies such as the FDA. Compliance with manufacturing standards, clinical trial requirements, and post-market surveillance is critical. Any delays or failures in regulatory approval can significantly impact market access and financial performance.

What Investors Should Do

1. Review newly filed exhibits for details on the July 2025 warrant inducement transaction.
2. Monitor future filings for updates on the 'At Market Issuance Sales Agreement' with Ladenburg Thalmann & Co. Inc.
3. Assess the implications of the license agreement with RF Innovations, Inc.

Key Dates

• 2025-09-03: Filing of S-1/A Amendment No. 1 — Indicates no changes to core financial or business sections, primarily an exhibits-only filing.
• 2025-07-22: Warrant Inducement Transaction — Issuance of Series B Warrant and Placement Agent Warrant, suggesting recent capital structure management.
• 2025-02-28: At Market Issuance Sales Agreement — Agreement with Ladenburg Thalmann & Co. Inc. for ongoing capital raising activities.
• 2024-11-22: Underwriting Agreement — Agreement with Ladenburg Thalmann & Co. Inc., indicating a formal capital raising arrangement.
• 2024-06-17: Executive Employment Agreements — Updated agreements for key executives Brad Hauser and Lori Bisson.
• 2024-01-19: Original Form 1-A POS Filing — Initial filing for certain incorporated exhibits, including corporate governance documents.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC, used to correct or update information previously filed. (This filing is an amendment to Autonomix Medical's S-1 registration statement.)

Exhibits

Supporting documents attached to SEC filings that provide further detail on the company's operations, agreements, and governance. (This filing is primarily an exhibits-only amendment, meaning new or updated supporting documents are being provided.)

Placement Agent Warrant

A warrant issued to a placement agent as compensation for their services in facilitating a private placement or offering. (A form of this warrant was filed as an exhibit, related to a July 2025 warrant inducement transaction.)

Amended and Restated Certificate of Incorporation

A document that modifies and replaces a company's original certificate of incorporation, outlining its fundamental corporate structure and powers. (An updated version was incorporated by reference, indicating changes to the company's foundational legal documents.)

At Market Issuance Sales Agreement

An agreement allowing a company to sell its shares 'at the market' through an agent, typically for ongoing capital raising. (Autonomix Medical has such an agreement with Ladenburg Thalmann & Co. Inc., suggesting continuous efforts to raise capital.)

Warrant Inducement Transaction

A transaction where a company offers existing warrant holders new warrants or other incentives to exercise their existing warrants or to amend their terms. (The company engaged in such a transaction in July 2025, impacting its capital structure.)

Year-Over-Year Comparison

This S-1/A Amendment No. 1, filed on September 3, 2025, is primarily an exhibits-only filing and indicates no changes to the core financial or business sections previously submitted. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or new risks against a prior financial statement period is not possible based on this amendment alone. The filing focuses on updating and incorporating exhibits related to recent capital-raising activities and corporate governance.

Filing Documents

• amix20250830_s1a.htm (S-1/A) — 70KB
• ex_858384.htm (EX-4.8) — 121KB
• 0001437749-25-028296.txt ( ) — 193KB

Exhibits and Financial Statement Schedules

Item 16. Exhibits and Financial Statement Schedules. (a) Exhibits : Exhibit Index Exhibit Number Description of Document 3.1 Amended and Restated Certificate of Incorporation of Autonomix Medical, Inc. (incorporated by reference from exhibit 2.1 of the Form 1-A POS, file number 024-12296, filed January 19, 2024) 3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Autonomix Medical, Inc., filed with the Secretary of State of the State of Delaware (incorporated by reference from exhibit 3.1 of the Form 8-K filed October 28, 2024) 3.3 Amended and Restated Bylaws of Autonomix Medical, Inc. (incorporated by reference from exhibit 2.2 of the Form 1-A POS, file number 024-12296, filed January 19, 2024) 4.1 Form of Warrant Agreement issued in SAFE offering (incorporated by reference from exhibit 3.1 of the Form 1-A POS, file number 024-12296, filed January 19, 2024) 4.2 Form of Selling Agent Warrant (incorporated by reference from exhibit 3.2 of the Form 1-A POS, file number 024-12296, filed January 19, 2024) 4.3 Form of Pre-Funded Warrant issued in November 2024 offering (incorporated by reference from exhibit 4.1 of the Form 8-K filed November 25, 2024) 4.4 Form of Series A Warrant issued in November 2024 offering (incorporated by reference from exhibit 4.2 of the Form 8-K filed November 25, 2024) 4.5 Form of Representative' s Warrant issued in November 2024 offering (incorporated by reference from exhibit 4.4 of the Form 8-K filed November 25, 2024) 4.6 Warrant Agency Agreement, dated November 22, 2024, with Equity Stock Transfer, LLC (incorporated by reference from exhibit 4.3 of the Form 8-K filed November 25, 2024) 4.7 Form of Series B Warrant issued in July 2025 warrant inducement transaction (incorporated by reference from exhibit 4.1 of the Form 8-K filed July 22, 2025) 4.8* Form of Placement Agent Warrant issued in July 2025 warrant inducement transaction 5.1 Opinion of Are

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Houston, Texas, on September 3, 2025. AUTONOMIX MEDICAL, INC. (Registrant) By: /s/ Brad Hauser Brad Hauser Chief Executive Officer and President Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the dates indicated: Date: September 3, 2025 By: /s/ Brad Hauser Brad Hauser Chief Executive Officer and President (Principal Executive Officer) Date: September 3, 2025 /s/ Trent Smith Trent Smith Chief Financial Officer (Principal Financial and Accounting Officer) Date: September 3, 2025 * Walter Klemp Executive Chairman of the Board of Directors Date: September 3, 2025 * Lori Bisson Vice Chair of the Board of Directors Date: September 3, 2025 * Jonathan Foster Director Date: September 3, 2025 * David Robins Director Date: September 3, 2025 * Christopher Capelli Director *By: /s/ Trent Smith Trent Smith Attorney-in-fact

View Full Filing

View this S-1/A filing on SEC EDGAR